These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 28303766)

  • 1. Prospects of combining adoptive cell immunotherapy with bortezomib.
    Pellom ST; Singhal A; Shanker A
    Immunotherapy; 2017 Mar; 9(4):305-308. PubMed ID: 28303766
    [No Abstract]   [Full Text] [Related]  

  • 2. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
    Huang H; Li F; Gordon JR; Xiang J
    Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimized adoptive T-cell therapy for the treatment of residual mantle cell lymphoma.
    Munger CM; Hegde GV; Weisenburger DD; Vose JM; Joshi SS
    Cancer Immunol Immunother; 2012 Oct; 61(10):1819-32. PubMed ID: 22441656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma.
    Batchu RB; Moreno AM; Szmania SM; Bennett G; Spagnoli GC; Ponnazhagan S; Barlogie B; Tricot G; van Rhee F
    Cancer Res; 2005 Nov; 65(21):10041-9. PubMed ID: 16267030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive cell therapy using PD-1
    Jing W; Gershan JA; Blitzer GC; Palen K; Weber J; McOlash L; Riese M; Johnson BD
    J Immunother Cancer; 2017; 5():51. PubMed ID: 28642819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.
    Shanker A; Pellom ST; Dudimah DF; Thounaojam MC; de Kluyver RL; Brooks AD; Yagita H; McVicar DW; Murphy WJ; Longo DL; Sayers TJ
    Cancer Res; 2015 Dec; 75(24):5260-72. PubMed ID: 26494122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulatory effect of DC/CIK combined with chemotherapy in multiple myeloma and the clinical efficacy.
    Zhao X; Ji CY; Liu GQ; Ma DX; Ding HF; Xu M; Xing J
    Int J Clin Exp Pathol; 2015; 8(10):13146-55. PubMed ID: 26722513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
    Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
    J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection.
    Basler M; Lauer C; Beck U; Groettrup M
    J Immunol; 2009 Nov; 183(10):6145-50. PubMed ID: 19841190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro.
    Jung SH; Lee YK; Lee HJ; Choi NR; Vo MC; Hoang MD; Lim MS; Nguyen-Pham TN; Kim HJ; Lee JJ
    Exp Hematol; 2014 Apr; 42(4):274-81. PubMed ID: 24407159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4+ and CD8+ T-cell responses in multiple myeloma patients.
    Reinhard H; Yousef S; Luetkens T; Fehse B; Berdien B; Kröger N; Atanackovic D
    Blood Cancer J; 2014 May; 4(5):e212. PubMed ID: 24813080
    [No Abstract]   [Full Text] [Related]  

  • 12. Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice.
    Zeis M; Frenzke H; Schmitz N; Uharek L; Steinmann J
    Bone Marrow Transplant; 2002 Feb; 29(3):213-21. PubMed ID: 11859393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance.
    de Haart SJ; van de Donk NW; Minnema MC; Huang JH; Aarts-Riemens T; Bovenschen N; Yuan H; Groen RW; McMillin DW; Jakubikova J; Lokhorst HM; Martens AC; Mitsiades CS; Mutis T
    Clin Cancer Res; 2013 Oct; 19(20):5591-601. PubMed ID: 24004671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells.
    Song W; Levy R
    Cancer Res; 2005 Jul; 65(13):5958-64. PubMed ID: 15994975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma.
    Jung SH; Lee HJ; Lee YK; Yang DH; Kim HJ; Rhee JH; Emmrich F; Lee JJ
    Oncotarget; 2017 Jun; 8(25):41538-41548. PubMed ID: 28088784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent immunotherapy against well-established thymoma using adoptively transferred transgene IL-6-engineered dendritic cell-stimulated CD8+ T-cells with prolonged survival and enhanced cytotoxicity.
    Kalyanasundaram Bhanumathy K; Zhang B; Xie Y; Xu A; Tan X; Xiang J
    J Gene Med; 2015; 17(8-9):153-60. PubMed ID: 26212685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular immunotherapy in multiple myeloma.
    Vo MC; Lakshmi TJ; Jung SH; Cho D; Park HS; Chu TH; Lee HJ; Kim HJ; Kim SK; Lee JJ
    Korean J Intern Med; 2019 Sep; 34(5):954-965. PubMed ID: 30754964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular immunotherapy in multiple myeloma: lessons from preclinical models.
    Binsfeld M; Fostier K; Muller J; Baron F; Schots R; Beguin Y; Heusschen R; Caers J
    Biochim Biophys Acta; 2014 Dec; 1846(2):392-404. PubMed ID: 25109893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm.
    Philippe L; Ceroi A; Bôle-Richard E; Jenvrin A; Biichle S; Perrin S; Limat S; Bonnefoy F; Deconinck E; Saas P; Garnache-Ottou F; Angelot-Delettre F
    Haematologica; 2017 Nov; 102(11):1861-1868. PubMed ID: 28798071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.
    Zou P; Kawada J; Pesnicak L; Cohen JI
    J Virol; 2007 Sep; 81(18):10029-36. PubMed ID: 17626072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.